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Osteopontin (OPN) is a multifunctional protein present in most tissues and body ﬂuids, with the highest
concentrations found in milk. Processes for isolation of OPN from bovine milk for use in infant formula
have been developed and studies have investigated the effects of oral administration of milk OPN. At the
same time, plasma OPN levels have been shown to be elevated in some types of cancer, and OPN has
been suggested as a potential diagnostic marker for cancer. OPN exists in several different isoforms
in vivo, of which presumably only a minority is directly or indirectly implicated in cancer related events.
In this article, we review the differences between milk-derived OPN and OPN derived from transformed
cells and compare the structure of OPN from human and bovine milk. Furthermore, current knowledge
about the function of OPN in milk and recent ﬁndings about the effect of orally presented OPN is
discussed.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Mammalian osteopontin (OPN) is an acidic highly phosphory-
lated glycoprotein containing the integrin binding ArgeGlyeAsp
(RGD) and SVVYGLR sequences. OPN is present in most tissues and
body ﬂuids (Sodek, Ganss, & McKee, 2000), with the highest con-
centrations found in milk (Schack et al., 2009a). OPN is a key
component in a variety of physiological processes such as inhibition
of ectopic calciﬁcation, bone remodelling, cancer metastasis and
immune modulatory functions (Anborgh, Mutrie, Tuck, &
Chambers, 2011; Sodek et al., 2000; Wang & Denhardt, 2008).r Ltd. This is an open access articleOPN can act as an opsonin, as it binds directly to several bacterial
strains leading to enhanced phagocytosis by macrophages (Schack
et al., 2009b). OPN is relatively resistant to proteolysis by neonatal
gastric juice (Chatterton, Rasmussen, Heegaard, Sørensen, &
Petersen, 2004) and can induce Th1 type immunity by inducing
interleukin-12 expression in macrophages (Ashkar et al., 2000).
This indicates that milk OPN could be an important factor in the
development of the immune system of infants.
Processes for isolation of OPN from bovine milk have been dis-
closed (Bertelsen, Wejse, & Trúgvason, 2014; Sørensen, Ostersen,
Chatterton, Holst, & Albertsen, 2007). OPN is isolated from bovine
whey using anion exchange technology and the ﬁnal product
contains ~78% protein of which 95% is OPN. OPN isolated by this
method (Lacprodan OPN-10) contains ash (max. 9%), moistureunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Post-translational modiﬁcation of bovine and human milk osteopontin (OPN). Phosphorylation and glycosylation sites are highlighted in black and grey, respectively (Christensen
et al., 2005; Sørensen et al., 1995). The regions containing the identiﬁed cleavage sites in bovine and human milk are boxed (Christensen et al., 2010; Christensen & Sørensen, 2014).
Exons 4 and 5 missing in OPN-c and OPN-b are indicated. The integrin binding RGD and SVVYGLR-motifs are underlined and introduced gaps are indicated by dashed lines.
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Dolan, & Ramanujam, 2014). The bovine milk OPN (in the form of
Lacprodan OPN-10) has been characterised by mass spectrometry
and functional studies, which showed that it is highly phosphory-
lated and glycosylated (Addison, Azari, Sørensen, Kaartinen, &
McKee, 2007). Milk OPN is very resistant to harsh conditions; e.g.,
heat treatment at 90 C has no effect on the post-translational
modiﬁcations decorating the protein (Sørensen, Højrup, & Petersen,
1995). Studies have investigated the beneﬁcial effects of oral
administration of milk OPN; however, at the same time, endoge-
nously expressed OPN has for long been considered a factor in cancer
related events (Anborgh et al., 2011; Bellahcene, Castronovo,
Ogbureke, Fisher, & Fedarko, 2008; Gimba & Tilli, 2013). Here we
review the differences between milk-derived OPN and OPN derived
from transformed cells (cancer model) and compare the structure of
OPN from human and bovine milk. Furthermore, we will review and
discuss current knowledge about the function of OPN in milk and
recent ﬁndings about the effect of orally presented OPN.
2. Structure and expression e comparison of human and
bovine milk osteopontin
Human OPN comprises 298 amino acids whereas the bovine
form only contains 262 residues, mainly because bovine OPN lacks
a sequence of 22 residues corresponding to residues 188e209 in
human OPN (Fig. 1). Comparison of the bovine and human OPN
sequences reveals that 182 amino acids are identical (61%) and anFig. 2. Osteopontin (OPN) expression in mammary gland and human milk cells: PCR of mam
or human OPN, or reverse transcription PCR performed using total RNA from human milk c
mammary gland cDNA library; lane 2, no template control. Panel B: lane M1, lambda mark
cDNA from human milk cells; lane 4, no template control.additional 44 residues retain high structural similarity. OPN is
encoded by a single copy gene, and during transcription human
OPN can undergo alternative splicing generating two splice variants
each lacking a single exon (Young et al., 1990). Moreover, OPN can
be post-translationally modiﬁed by especially phosphorylation, O-
glycosylation, and proteolytic processing (Kazanecki, Uzwiak, &
Denhardt, 2007b; Qin, Baba, & Butler, 2004) leading to the exis-
tence of numerous OPN isoforms (Fig. 1). OPN isoforms are cell and
tissue-speciﬁc and OPN expressed by different cell-types or under
different conditions have been shown to be functionally different
(Christensen et al., 2007; Christensen, Kl€aning, Nielsen, Andersen,
& Sørensen, 2012; Kazanecki et al., 2007b).
We have performed PCR analysis on a bovine mammary gland
cDNA library using gene-speciﬁc primers that revealed only a single
transcript with a size of ~1045 base pairs (Fig. 2A), which is the
expected size without alternative splicing. Similarly, we analysed
the existence of differential RNA splicing from both a human
mammary gland cDNA library and by reverse transcription-PCR of
milk cells from twowomen. In all cases, only a single transcript was
observed and no alternative splicing was detected (Fig, 2B) indi-
cating that alternative splicing of OPN does not occur in bovine and
human milk. These results are in accordance with other studies
showing that alternative OPN splicing in both human and bovine
milk is undetectable in normal specimens (Bissonnette,
Dudemaine, Thibault, & Robitaille, 2012; Mirza et al., 2008).
In both bovine and humanmilk, OPN is very prone to proteolytic
cleavage close to the RGD- and SVVYGLR sequences and hence amary gland cDNA libraries using primers encompassing the coding sequence of bovine
ell transcripts. Panel A: lane M1, lambda marker; lane M2, pUC marker; lane 1, bovine
er; lane M2, pUC marker; lane 1, human mammary gland cDNA library; lanes 2 and 3,
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exposed integrin binding motifs (Fig. 1) (Bissonnette et al., 2012;
Christensen, Schack, Kl€aning, & Sørensen, 2010; Christensen &
Sørensen, 2014). Proteolytic cleavage close to the integrin binding
motifs has been demonstrated to increase the integrin binding
properties of OPN (Agnihotri et al., 2001; Christensen et al., 2010;
Yokosaki, Tanaka, Higashikawa, Yamashita, & Eboshida, 2005).
OPN is highly phosphorylated in milk with ~25 phosphates
distributed over 36 potential sites (34 serines and 2 threonines) in
the humanmilk OPN (Christensen et al., 2012; Christensen, Nielsen,
Haselmann, Petersen, & Sørensen, 2005) and ~22 phosphates
distributed over 28 potential sites in bovine milk OPN (Boskey,
Christensen, Taleb, & Sørensen, 2012; Sørensen et al., 1995). The
phosphorylations are arranged in clusters of 3e5 phosphoresidues
and are predominantly located in the target sequence of the kinase
FAM20C (Tagliabracci et al., 2012). Bovine milk OPN contains three
O-glycosylated threonine residues close to the integrin binding
motifs (Fig. 1) (Sørensen et al., 1995). These threonine residues are
well conserved among all analysedmammalian OPN sequences and
are also glycosylated in human milk (Christensen et al., 2005).
Human milk OPN contains two additional threonine-linked oligo-
saccharides on less well conserved threonines (Fig. 1). The glycan
structures on human milk OPN have been shown to consist of large
fucosylated N-acetyllactosamine units (Christensen et al., 2012),
whereas the carbohydrates on bovine OPN consist of a disialylated
GalNAc-galactose cores (Boskey et al., 2012; Christensen et al.,
2007; Christensen, Petersen, & Sørensen, 2008). The functional
role of OPN glycosylation inmilk is not clear, but their location close
to the integrin binding motifs could suggest a protective role of the
carbohydrates against cleavage by endogenous milk proteases.
Alignment of the amino acid sequences (Fig. 1) show that all
structural important elements, like the integrin binding sequences,
sites for post-translational modiﬁcation and regulatory proteolytic
cleavage sites are well conserved between human and bovine OPN.
3. Role of osteopontin in milk
OPN is present in many tissues and excretions, but by far the
highest concentration of the protein is found in milk. Human milk
contains ~138 mg mL1 and bovine milk contains ~18 mg mL1
(Schack et al., 2009a). In comparison, the OPN concentrations in
adult human plasma and urine have been measured to be
~35 ng mL1 and ~4 mg mL1, respectively (Kolbach et al., 2012;
Schack et al., 2009a), and recently it was estimated that bovine
plasma contains ~40 ng mL1 OPN (Dudemaine, Thibault, Alain, &
Bissonnette, 2014). The high level of OPN expression in human
milk persists throughout the lactation period, and OPN, which
possess known cytokine-like properties, was the most abundantly
expressed when compared with the expression of 240 cytokine
related genes in human milk (Nagatomo et al., 2004). Furthermore,
the levels of OPN in the umbilical cord and infants' plasma are 7e10
times higher than in adult plasma (Schack et al., 2009a). Collec-
tively, this suggests that OPN plays a role in the development of the
infant and could provide an important immunological signal during
development as will be discussed later.
OPN has been reported to be involved in mammary gland
development and differentiation, as transgenic mice expressing OPN
antisense-RNA have severe lactation deﬁciency and display a lack of
mammary alveolar structures (Nemir et al., 2000). In contrast to
these transgenic mice, OPN knockout mice are both fertile, lactating
and produce a normal litter size (Rittling et al., 1998).
Milk OPN is a very acidic protein due to a high degree of nega-
tively charged amino acids and the many phosphorylations deco-
rating the protein. This intrinsic property allows OPN to bind and
form soluble complexes with calcium ions, which together withespecially the caseins, could inhibit unintentional precipitation of
amorphous calcium phosphate in milk (Holt, Lenton, Nylander,
Sørensen, & Teixeira, 2014; Holt, Sørensen, & Clegg, 2009;
Kl€aning, Christensen, Sørensen, Vorup-Jensen, & Jensen, 2014).
In vivo models using OPN-deﬁcient mice have supported an
inhibitory function of the protein in ectopic calciﬁcation (Ohri,
Tung, Rajachar, & Giachelli, 2005; Steitz et al., 2002).
OPN can induce the expression of the Th1 cytokine interleukin-
12 and inhibit the production of the Th2 cytokine, interleukin-10
(Ashkar et al., 2000). Hence OPN is a key cytokine in the regula-
tion of the Th1/Th2 balanced immune response. Interestingly,
phosphorylation of OPN is necessary for the induction of
interleukin-12 expression (Ashkar et al., 2000). The generation of a
Th1 response is essential for the clearance of intracellular patho-
gens, and OPN-deﬁcient mice aremore susceptible to both viral and
bacterial infections than wild type mice (Ashkar et al., 2000; Nau
et al., 1999). Thus, breast milk OPN could be hypothesised to pro-
tect infants against infections by inducing a Th1 immune response.
This correlates with an observed difference in the induction of a
Th1-like response in breast-fed, but not formula-fed, infants after
immunisation against measles, mumps, and rubella (Pabst et al.,
1997). Furthermore, milk OPN can induce the expression of
interleukin-12 from intestinal mononuclear cells (Schack et al.,
2009a). Human and bovine milk OPN have been shown to be
resistant to proteolysis by neonatal gastric juices at pH 3.0 for 1 h at
37 C (Chatterton et al., 2004) indicating that ingested milk OPN
could contribute to polarise the immune system in a Th1 direction
at the gut mucosal surface of infants.
OPN-knockout suckling mice are more susceptible to rotavirus
infection and show more intense and prolonged diarrhoea than
wild-type suckling mice (Maeno et al., 2009). OPN has also been
shown to bind directly to bacteria and to enhance phagocytosis of
these (Schack et al., 2009b). Likewise, OPN reduces dental bioﬁlm
formation by binding to the surface of bacterial cells (Schlafer et al.,
2012). This suggests that OPN in milk can also play a more direct
role in the immune defence by interacting directly with invading
pathogens.
In milk, OPN can form complexes with lactoferrin, lactoperox-
idase and IgM through electrostatic or afﬁnity interactions (Azuma,
Maeta, Fukuchi, & Kanno, 2006). OPN has therefore been hypoth-
esised to act as a transporter of these immunomodulating and
antimicrobial proteins to their site of action and to protect them
from proteolysis (Azuma et al., 2006; Yamniuk, Burling, & Vogel,
2009). Thus, OPN can in several different ways contribute to the
defence against pathogens in milk and thereby also in the neonate
or infant.
4. Osteopontin and cancer e same gene but different protein
Human OPN has been associated with cancer development
(Anborgh et al., 2011; Bellahcene et al., 2008). Clinically, OPN has
been suggested as a potential biomarker in some cancer types,
where its expression has been associatedwith disease progression in
several cancer forms (Bellahcene et al., 2008; Shevde & Samant,
2014). In vitro and in vivo, OPN has been reported to inﬂuence the
behaviour of cancer cells in a manner that promotes malignancy,
including cell survival, proliferation, invasion, angiogenesis and
metastasis at distant sites (Bellahcene et al., 2008; Shevde& Samant,
2014). Plasma OPN levels in different cancer patients are elevated to
115e198 ng mL1 (Bramwell et al., 2006; Hotte, Winquist, Stitt,
Wilson, & Chambers, 2002; Ramankulov et al., 2007; Singhal et al.,
1997). This is signiﬁcantly higher compared with the OPN level in
healthy adults of ~30e45 ng mL1 (Ramankulov et al., 2007; Schack
et al., 2009a; Singhal et al., 1997). Though, the OPN concentrations in
the umbilical cord (263 ng mL1) and infants' plasma (342 ng mL1)
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high OPN plasma levels cannot exclusively be connected with cancer
processes. These plasma levels also indicate that OPN plays a role in
the normal developmental processes taking place in the growing
infant.
It is not clear whether the elevated OPN expression observed in
cancer patients is part of the disease process or whether it is an
immunological response to the cancer. Neither is it clear whether
the OPN expressed by the transformed cells in the tumour is the
same as the OPN expressed by the normal cells in the body. It has
been suggested that the two forms of OPN have different structure
and function, as host-derived OPN has been observed to act as a
macrophage chemoattractant, whereas tumour-derived OPN
enhanced growth and survival of metastases (Crawford, Matrisian,
& Liaw, 1998). Post-translational modiﬁcation can regulate the
function of OPN in physiological and pathological processes, and
most tumour cells appear to express hypophosphorylated OPN
(Anborgh et al., 2011). For instance, normal rat kidney cells secrete
both phosphorylated and non-phosphorylated OPN (Nemir,
DeVouge, & Mukherjee, 1989). However, after transformation of
the cells the expression of non-phosphorylated OPN was signiﬁ-
cantly increased and expression of phosphorylated OPN was
decreased. The OPN gene is responsive to ras (Guo, Zhang, Mitchell,
Denhardt, & Chambers, 1995), which is an oncogene, and ras-mu-
tations are frequently observed in cancer cells (Downward, 2003).
Therefore ras-transformed cells can be used as a model for cancer
cell modiﬁcation of OPN. We have compared the expression of OPN
in ras-transformed ﬁbroblast with the expression in the parental
non-transformed cells using different monoclonal antibodies rec-
ognising sites that potentially can be phosphorylated. It is clear that
the OPN produced by the two versions of the cells are structurally
different, and that the OPN produced by the ras-transformed cells
are not phosphorylated to the same degree as the OPN produced by
the normal cells (Fig. 3). This is in line with previous character-
isations of OPN forms (Kazanecki, Kowalski, Ding, Rittling, &
Denhardt, 2007a) and in particularly with an analysis of OPN
from lactating mammary glands of mice compared with OPN from
mammary tumours arising from ras-transformation. This analysis
showed a signiﬁcant difference between the two OPN forms
(Rittling & Novick, 1997), which most likely could be attributed to a
difference in phosphorylation of the OPN isoforms. In a more direct
analysis, only four phosphate groups were identiﬁed on OPN
expressed by ras-transformed ﬁbroblasts making it the least
phosphorylated OPN form described so far (Christensen et al.,
2007). This low level of phosphorylation of OPN from trans-
formed cells is in strong contrast to milk OPN which is highly
phosphorylated and contains 22e25 phosphate groups (Boskey
et al., 2012; Christensen et al., 2012).
OPN pre-mRNA consists of 7 exons (Young et al., 1990); however,
two splice variants with deletions of exon 4 (OPN-c) or exon 5
(OPN-b) have been described in humans (Fig. 1). Though theFig. 3. Monoclonal antibody recognition of osteopontin (OPN) from ﬁbroblasts and
ras-transformed ﬁbroblasts. Western blotting results showing monoclonal antibody
recognition of OPN from non-transformed murine 3T3 ﬁbroblasts (lane 1) or from ras-
transformed murine ﬁbroblasts (lane 2). The ras-transformed cells were derived from
the parental line 3T3-275 by transformation with rasval12 (Wu, Denhardt, & Rittling,
2000). The epitopes for the antibodies are P190VA192 for 2A1, K283FRISHELDSAS-
SEVN298 for 3D9, and Y149GLRSKS154 for m53 (Anborgh et al., 2009; Kazanecki et al.,
2007a), and mab193P and mab197P have unspeciﬁed epitopes in the N- and C-ter-
minal parts of osteopontin, respectively (Plumer et al., 2008).expression and functional roles of the different isoforms is unclear,
OPN-C is speciﬁcally expressed in different tumours such as
ovarian, prostate, breast cancer tissues where this isoform has
shown malignancy-promoting effects (Gimba & Tilli, 2013). How-
ever, alternative splicing does not occur in the OPN expressed in
milk as mentioned earlier.
In conclusion, though OPN is coded by a single gene, many
isoforms exists and milk OPN and cancer derived-OPN seem to be
structurally different. There is no indication that milk OPN should
be involved in cancer development. On the contrary, in a recent
study mice were injected with ras-transformed ﬁbroblastic tumour
cells, and it was demonstrated that oral intake of water containing
300 mg L1 bovine milk resulted in a signiﬁcant reduction in the
growth rate and size of the tumours (Rittling, Wejse, Yagiz, Warot,
& Hui, 2014). The mechanism for this suppression of tumour
growth was related to angiogenesis, as tumours from OPN fed mice
had abnormally large blood vessels which were speculated to be a
consequence of insufﬁcient nutrient transfer of the vessels or that
they could be inherently unstable (Rittling et al., 2014).
5. Oral administration of milk osteopontin
Human breast milk contains ~138 mg L1 OPN, which corre-
sponds to ~2.1% (w/w) of the total protein in human milk. Bovine
milk contains ~18 mg L1 and standard infant formula contains on
average only ~9 mg L1 OPN (Schack et al., 2009a). Bovine and
human milk OPN are structurally very similar with regard to amino
acid sequence and phosphorylation pattern, and both proteins are
O-glycosylated in the same region of the protein. Therefore it is
suggested to use bovine OPN in infant formulas to close the con-
centration gap to human milk (Boskey et al., 2012; Christensen
et al., 2012, 2005; Sørensen et al., 1995).
As a natural occurring milk protein and as such part of the
natural optimal diet for infants, it seems evident that oral intake of
milk OPN should not be harmful in any way. Though, as it is a new
component proposed for use in infant formula, it has been sub-
jected to safety evaluations. A proprietary whey-based protein
product (Lacprodan OPN-10) that contains approximately 95%
bovine milk OPN has been tested and found not to be genotoxic
in vitro and in vivo (Kvistgaard et al., 2014). Lacprodan OPN-10 has
been used as a source of bovine milk OPN in several studies
investigating the effect of oral intake of OPN. For instance, studies
showed that intake of a diet with up to 2% Lacprodan OPN-10 for
91 d was not toxic nor did it affect general health, growth or was
teratogenic when administered to pregnant Wistar rats (Kvistgaard
et al., 2014).
Recent studies have shown that supplementing formulas with
Lacprodan OPN-10 have beneﬁcial effects on formula fed offspring
and infants. In a studywith infant rhesus monkeys, OPNwas shown
to have a large impact on the genes expressed in the intestine
(Donovan et al., 2014a). From birth to 3months of age, infant rhesus
monkeys were exclusively breastfed, fed normal formula without
OPN or formula containing 125 mg L1 bovine milk OPN. Addition
of OPN to the formula did not result in any difference in overall
neonatal growth, body composition or blood immune cell compo-
sition. However, microarray analysis of the small intestinal tran-
scriptome showed that 1017 genes were differently expressed
between the formula-fed and breastfed rhesus infants, but addition
of OPN to the formula reduced the difference to 217 genes
(Donovan et al., 2014a). This demonstrates that bovine milk OPN at
a concentration comparable with what is found in human milk
shifts the gene expression in the intestine to be more similar to that
found in breast-fed infants.
The effect of adding bovine milk OPN (Lacprodan OPN-10) to
formula has also recently been investigated in human infants
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randomised controlled trial, mothers either breast- or formula-fed
their infants from 1 to 6 months of age. The formula-fed infants
received either standard formula or formula with 65 mg L1 or
130 mg L1 OPN (double-blinded). The study showed that addition
of OPN changed the plasma levels of several amino acids and cy-
tokines in formula-fed infants to be more similar to what was
observed in breast-fed infants, though not all changes were sta-
tistically signiﬁcant. Interestingly, addition of OPN to formula
signiﬁcantly lowered the levels of the pro-inﬂammatory cytokine
TNF-a but signiﬁcantly increased levels of interleukin-2 that plays
key roles in oral tolerance (L€onnerdal et al., 2015). Importantly,
there were no differences in appetite, growth, weight or height
among the different infant groups (L€onnerdal et al., 2015).
Furthermore, the groups that received OPN containing formulas
had signiﬁcant less fever days than the group that received stan-
dard infant formula (L€onnerdal et al., 2015). Supplementing infant
formula with 65 mg L1 OPN was also indicated to support
improved immune development in infants, as it signiﬁcantly shif-
ted the gene expression of peripheral bloodmononuclear cells to be
more similar to breast-fed infants (Donovan et al., 2014b).
A considerable amount of ingested OPN is likely to be digested
by duodenal and gastric proteases, however a concentration of
~1050 ngmL1 bovinemilk OPNhas beenmeasured inplasma ofmice
that had received 200 mg of bovine milk OPN by gavage (da Silva et al.,
2009). In another study, 50mgOPNdissolved in chocolatemilkwas fed
to OPN knockout mice, and after 4 h ~5000 ng mL1 OPN could be
measured in their plasma (Rittling et al., 2014). By immunohisto-
chemistry, it has also been demonstrated that orally ingested OPN can
be found in the colon mucosa of mice (da Silva et al., 2009). Thus, it is
strongly indicated that some ingested OPN survives passage though
the digestive system, and can potentially exert its function at the gut
mucosal surfaces. In fact, administration of exogenous bovine milk
OPN, and not unphosphorylated OPN, in the drinking water had a
protective effect on several disease parameters in a mouse model of
colitis (da Silva et al., 2009). This is in line with a study showing
exacerbated tissue destruction and reduced repair in OPN-deﬁcient
mice compared with wild-type mice in an acute colitis model (da
Silva et al., 2006). In addition, oral intake of a physiological concen-
trationofbovinemilkOPNprotectedagainst liver injuryduring chronic
alcohol feeding of mice (Ge, Lu, Leung, Sørensen, & Nieto, 2013). The
mechanism involved OPN binding to lipopolysaccharide preventing
lipopolysaccharide translocation from the gut which is important for
the onset of alcoholic liver disease, as it promotes macrophage inﬁl-
tration and activation and hence liver injury (Ge et al., 2014).
6. Conclusion
OPN is complex protein expressed in many tissues and body
ﬂuids, with the highest concentrations in milk. OPN is involved in
both pathological and normal physiological processes and the
protein exists in many different isoforms resulting from alternative
splicing and post-translational modiﬁcation. Human and bovine
milk OPN are expressed as single transcripts without alternative
splicing and both are highly phosphorylated. In contrast, cancer-
derived OPN often undergoes alternative splicing and are not or
poorly phosphorylated. Oral administration of bovine milk OPN has
shown promising results in infant nutrition and has been shown to
attenuate colitis and alcohol-induced liver injury.
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